SUMO2 (Small Ubiquitin-Like Modifier 2) is a member of the SUMO family of ubiquitin-like proteins that play critical roles in regulating protein function, localization, and stability through a reversible post-translational modification process called SUMOylation. This modification regulates numerous cellular processes including transcription, DNA repair, mitochondrial function, and protein degradation. Growing evidence implicates SUMOylation dysregulation in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
| SUMO2 Protein | |
|---|---|
| Protein Name | Small Ubiquitin-Like Modifier 2 |
| Gene | SUMO2 |
| UniProt ID | P61956 |
| Alternative Names | SUMO-2, Sentrin-2, SMT3C |
| Molecular Weight | 10.9 kDa |
| Length | 95 amino acids |
| Subcellular Localization | Nucleus, Cytoplasm, Nuclear Pore Complex |
| Protein Family | SUMO family, Ubiquitin-like proteins |
SUMO2 is a member of the SUMO (Small Ubiquitin-Like Modifier) protein family that mediates reversible post-translational modification through a process called SUMOylation 1. Unlike ubiquitination, which typically targets proteins for degradation, SUMOylation modulates protein function, localization, and interactions in diverse ways. SUMO2 is particularly important for stress-responsive SUMOylation, as it becomes rapidly conjugated to proteins in response to cellular stress including heat shock, oxidative stress, and DNA damage 2.
The SUMOylation pathway involves an E1 activating enzyme (SAE1/SAE2), an E2 conjugating enzyme (UBC9), and various E3 ligases that provide substrate specificity. SUMOylation is reversible through the action of SUMO-specific proteases (SENPs) that cleave SUMO from substrates 3. This dynamic modification regulates hundreds of proteins involved in transcription, DNA repair, mitochondrial function, and protein quality control.
In the nervous system, SUMOylation plays crucial roles in neuronal development, synaptic plasticity, and response to neurodegeneration. Dysregulated SUMOylation has been implicated in multiple neurodegenerative diseases, where it affects the aggregation, clearance, and toxicity of disease-associated proteins including amyloid-beta, tau, alpha-synuclein, and huntingtin 4.
SUMO2 shares structural homology with ubiquitin but has distinct features:
SUMO2 can form poly-SUMO chains through conjugation at Lysine 11 (K11), which is distinct from SUMO1 that typically functions as a monomer. These chains regulate different cellular processes and can serve as signals for protein degradation or altered protein interactions 5.
SUMO2 is the primary SUMO paralog involved in stress-responsive SUMOylation:
SUMO2ylation controls transcription factor activity:
SUMO2ylation regulates mitochondrial dynamics:
SUMO2 plays a role in protein homeostasis:
SUMO2ylation is significantly altered in Alzheimer's disease:
A key finding is that SUMO2 conjugation to proteins is globally increased in AD brain, reflecting cellular stress response 6. Conversely, the enzymes that remove SUMO2ylation (SENPs) are often downregulated, leading to accumulation of SUMO2ylated proteins.
SUMO2 plays complex roles in PD pathogenesis:
SUMO2ylation of alpha-synuclein has been shown to reduce its aggregation and toxicity in cellular models, suggesting therapeutic potential 7.
SUMO2 dysregulation contributes to Huntington's disease:
SUMO2 plays a role in ALS pathogenesis:
Targeting SUMOylation represents a therapeutic strategy:
SUMO2 and SUMOylated proteins serve as biomarkers:
The study of Sumo2 Protein Small Ubiquitin Like Modifier 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hay RT. (2013). SUMO: a history of modification. Molecular Cell 58(1): 1-12.
Bersch B, et al. (2014). Structural basis for SUMO chain formation. Molecular Cell 55(4): 581-597.
Last updated: 2026-03-07